Triple-negative breast cancer (TNBC) accounts for 10–15% of all breast cancers and the clinical course of TNBC and the risk factors are known to be different from those of estrogen receptor (ER)-positive cancers [1]. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.